2020: A molecular odyssey – could artificial intelligence bring in a new age of antibiotic drug discovery?
Using machine-learning, researchers have discovered a new antibiotic that is able to kill bacteria resistant to other antibiotics.
Browsing: Antibiotics
Does drug tolerance promote antibiotic resistance despite combination therapy?
When investigating the effect tolerance to a single drug has when combination therapy is being used to prevent antibiotic resistance, a team of researchers demonstrated that antimicrobial tolerance can promote resistance.
US FDA approves first siderophore antibiotic, cefiderocol (Fetroja)
The US FDA has approved cefiderocol (Fetroja), a siderophore cephalosporin that inhibits bacterial cell wall synthesis. Fetroja is the first approved antibiotic that functions as a siderophore.
Antibiotic-loaded nanomesh developed for drug delivery
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.
A peek behind the paper – Shujuan Sun on using existing antibiotics as antifungals
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
IDWeek: Antibiotics before dental visits are overprescribed and increase the risk of side effects
Research has suggested that prophylactic antibiotics are overprescribed before dental visits, and that taking them could actually increase the likelihood of adverse effects.
Combating resistance while maintaining innovation: The future of antimicrobial stewardship
In this perspective piece for Future Microbiology the authors argue that there is a lack of innovation to meet the current shortcomings of antibiotic R&D.
First new oral and IV antibiotic with novel mechanism of action approved in nearly two decades
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
US FDA approves RECARBRIO™ for complicated UTIs and complicated intra-abdominal infections: July’s industry headlines
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
Infographic: Gonorrhea – a timeline of resistance and it’s mechanisms
In this infographic we give you a visual snapshot of the antibiotics introduced for gonorrhea and a timeline of when resistance was first identified, in addition to setting out some of the primary resistance mechanisms.
